University of Oxford Confidence in Concept – Round 7
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding
People |
ORCID iD |
| Matthew Wood (Principal Investigator) |
Publications
Adigbli G
(2021)
Development of LT-HSC-Reconstituted Non-Irradiated NBSGW Mice for the Study of Human Hematopoiesis In Vivo.
in Frontiers in immunology
Adigbli G
(2023)
Complex Lymphatic Drainage in Head and Neck Cutaneous Melanoma and SLNB Outcomes
in JAMA Otolaryngology-Head & Neck Surgery
Alzhrani A
(2020)
Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use.
in Cellular immunology
Badat M
(2023)
Direct correction of haemoglobin E ß-thalassaemia using base editors.
in Nature communications
Beckett J
(2021)
Poor Antibody Responses to SARS-CoV-2 Infection or Vaccination Are Associated With High Re-Infection Rates in Haemodialysis and Renal Transplant Patients
in SSRN Electronic Journal
Benjamin K
(2024)
Multiscale topology classifies cells in subcellular spatial transcriptomics.
in Nature
Bissett C
(2024)
Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.
in NPJ vaccines
Bottomley MJ
(2022)
Towards regulatory cellular therapies in solid organ transplantation.
in Trends in immunology
Brook M
(2019)
New frontiers: cellular immunotherapy beyond cancer
in Cell and Gene Therapy Insights
Cendales L
(2024)
Banff 2022 Vascularized Composite Allotransplantation Meeting Report: Diagnostic criteria for vascular changes
in American Journal of Transplantation
Cross A
(2023)
Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury
in JCI Insight
Deli A
(2023)
The Design of Brainstem Interfaces: Characterisation of Physiological Artefacts and Implications for Closed-loop Algorithms.
in International IEEE/EMBS Conference on Neural Engineering : [proceedings]. International IEEE EMBS Conference on Neural Engineering
Escoto M
(2023)
Research and Innovation in Organ Donation: Recommendations From an International Consensus Forum
in Transplantation Direct
Fry LE
(2020)
Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency.
in The CRISPR journal
Fry LE
(2021)
Analysis of Pathogenic Variants Correctable With CRISPR Base Editing Among Patients With Recessive Inherited Retinal Degeneration.
in JAMA ophthalmology
Grba DN
(2024)
Molecular mechanism of the ischemia-induced regulatory switch in mammalian complex I.
in Science (New York, N.Y.)
Hansen S
(2023)
Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases.
in Cells
Hennessy C
(2023)
Barriers to Treg therapy in Europe: From production to regulation.
in Frontiers in medicine
Hennessy C
(2021)
Recent advances in our understanding of the allograft response
in Faculty Reviews
Hoogduijn MJ
(2021)
Cellular therapies in organ transplantation.
in Transplant international : official journal of the European Society for Organ Transplantation
Issa F
(2022)
Editorial: Regulatory T Cells
in Frontiers in Cell and Developmental Biology
Issa F
(2021)
The Fourth International Workshop on Clinical Transplant Tolerance.
in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Issa F
(2023)
IL-21-producing Alloreactive T Cells Expand in Parallel to Donor-specific Antibodies
in Transplantation
Kaiser D
(2021)
Freezing Medium Containing 5% DMSO Enhances the Cell Viability and Recovery Rate After Cryopreservation of Regulatory T Cell Products ex vivo and in vivo.
in Frontiers in cell and developmental biology
Kantor A
(2020)
CRISPR-Cas9 DNA Base-Editing and Prime-Editing.
in International journal of molecular sciences
Kantor A
(2021)
CRISPR genome engineering for retinal diseases.
in Progress in molecular biology and translational science
Kaukonen M
(2022)
CRISPR DNA Base Editing Strategies for Treating Retinitis Pigmentosa Caused by Mutations in Rhodopsin.
in Genes
Leng H
(2024)
Blocking glycosphingolipid production alters autophagy in osteoclasts and improves myeloma bone disease.
in Autophagy
Leng H
(2022)
Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease.
in Nature communications
Lim TY
(2023)
Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans.
in Journal of hepatology
Mohseni YR
(2021)
Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive.
in European journal of immunology
O'Neil A
(2023)
A GMP Protocol for the Manufacture of Tregs for Clinical Application.
in Methods in molecular biology (Clifton, N.J.)
Peddle CF
(2020)
CRISPR Interference-Potential Application in Retinal Disease.
in International journal of molecular sciences
Pilat N
(2022)
Joining Forces in Basic Science: ITS Meeting 2.0.
in Transplant international : official journal of the European Society for Organ Transplantation
Quinn J
(2021)
Genome-Editing Strategies for Treating Human Retinal Degenerations.
in Human gene therapy
Short S
(2024)
Reference Module in Life Sciences
Stark HL
(2021)
Immune Monitoring for Advanced Cell Therapy Trials in Transplantation: Which Assays and When?
in Frontiers in immunology
Staurenghi F
(2022)
Minicircle Delivery to the Neural Retina as a Gene Therapy Approach.
in International journal of molecular sciences
Stevanovic M
(2022)
CRISPR Systems Suitable for Single AAV Vector Delivery.
in Current gene therapy
VanDyke D
(2022)
Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection.
in Cell reports
Wing PAC
(2022)
Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.
in PLoS pathogens
Wright S
(2022)
Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Transplantation
in Engineering
Zamora M
(2022)
DyNeuMo Mk-1: Design and pilot validation of an investigational motion-adaptive neurostimulator with integrated chronotherapy.
in Experimental neurology
| Description | BRAINSTATE - To develop the DyNeuMo device for use in minimally conscious state (Alex Green) |
| Amount | £697,119 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 07/2025 |
| Description | Developing CRISPR delivery strategies for the treatment of inherited retinal diseases |
| Amount | £60,000 (GBP) |
| Organisation | The Royal College of Surgeons of Edinburgh |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 09/2021 |
| Description | ReSHAPE |
| Amount | £151,875 (GBP) |
| Funding ID | 825392 |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 01/2019 |
| End | 12/2023 |
| Description | UCB Pharma |
| Organisation | UCB SA |
| Department | UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The key preliminary data generated by this project has been used to successfully negotiate a new partnership with our industrial collaborator UCB Pharma |
| Collaborator Contribution | providing antibody production to take place with no associated costs required from Oxford. |
| Impact | n/k |
| Start Year | 2022 |
| Title | MODULATING WAKEFULNESSS AND AROUSAL |
| Description | Arousal of a patient is enhanced and wakefulness modulated by neurostimulation. Bioelectrical activity of the nervous system of the patient is monitored and characteristics of the monitored bioelectrical activity associated with a state of reduced arousal and/or wakefulness are detected. In response to such characteristics, stimulation signals selected to arouse the patient are generated and supplied to stimulation transducers to stimulate a neural network of a patient associated with arousal. |
| IP Reference | WO2022200814 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | NK |
| Description | Experts in Residence meeting with Astra Zeneca |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Industry/Business |
| Results and Impact | The purpose of the session was to discuss the longer term translational implications of the project via the experts in residence scheme. A wealth of information was transmitted to our research team on the validation routes for the project and how to consolidate the engagement and the collaboration prospects on this award. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Industry engagement activities with Kymab / Sanofi |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The project team has been discussing a collaboration project with Kymab / Sanofi. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Industry engagement activities with UCB Pharma - (Alison Simmons) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Discussing potential licensing agreement, pending data from larger sets of efficacy studies and safety/toxicology profiling of our monoclonal antibodies. |
| Year(s) Of Engagement Activity | 2021 |